newsfilter
← Latest News
Business Wire·

Bayer and Iambic Collaborate to Advance Drug Discovery with AI

  • Bayer & Iambic Therapeutics announced a drug discovery collaboration focused on small molecule discovery.
  • The partnership leverages Iambic's AI platform, including Enchant & NeuralPLexer, to identify novel drug entry points for hard-to-drug targets.
  • The initiative aims to accelerate optimization timelines, strengthen Bayer's early pipeline, & address the high failure rate of traditional drug candidates.
  • Iambic will receive an upfront payment along with milestone & royalty payments under the agreement terms.
  • Bayer's R&D expenses for fiscal 2025 were 5.8 billion euros, while Iambic's platform has previously advanced a drug candidate to clinical trials in one-third of the industry-standard time.